Picture this: a seemingly ordinary wrist swelling spirals into a rare bacterial battle that challenges everything we know about treating infections in vulnerable patients. This isn't just any case—it's a wake-up call for how we handle uncommon pathogens in compromised immune systems.
- Case Report
- Open access (https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research)
Published: 22 November 2025
Camille Elbaz¹,
Y. Hamidou⁴,
M. Choquet²,
P-A. Bruy¹⁴,
M. Doussiere¹⁴,
J. P. Lanoix³ &
…
V. Goeb⁴
BMC Infectious Diseases (https://bmcinfectdis.biomedcentral.com/) , Article number: (2025) Cite this article
We're sharing an unedited manuscript here to provide early access to its key findings. Keep in mind that before the final version is out, it will go through more editing. There might be some errors that could impact the content, and all standard legal disclaimers still apply.
Abstract
Background
Septic arthritis in the wrist is uncommon and typically stems from Staphylococcus aureus. However, Gemella haemolysans rarely plays a role in bone and joint infections, with most reports focusing on artificial joint infections or discitis in the spine.
Case presentation
A 45-year-old female undergoing hemodialysis, who also had a co-infection of hepatitis B and HIV (with a CD4 count of 152 cells per microliter) along with untreated multiple myeloma, came in with a fever lasting 10 days reaching 39.5°C and noticeable swelling in her right wrist. Cultures from her synovial fluid and blood confirmed the presence of G. haemolysans, identified with a MALDI-TOF score of 2.31. The minimum inhibitory concentrations (MICs) were: amoxicillin at 0.5 mg/L, clindamycin at 0.5 mg/L, and gentamicin at 16 mg/L. An echocardiogram ruled out any heart valve issues like endocarditis. Initial treatment with amoxicillin alone (3g per day intravenously, adjusted for her kidney function) didn't bring about any improvement in her symptoms or lab results. Adding clindamycin at 600mg intravenously every 6 hours led to a full recovery of symptoms and the normalization of inflammation markers after five weeks of the combined therapy.
Conclusion
This report highlights the potential shortcomings of using beta-lactam antibiotics alone for infections in natural joints caused by G. haemolysans, particularly in those with weakened immune systems. The amoxicillin's failure might stem from poor penetration into joint tissues, the lack of surgical cleaning of the area, and relying on drug effectiveness guidelines that haven't been thoroughly tested for this unusual bacterium. Quick reassessment and switching to combination treatments could be crucial, especially for immunocompromised individuals.
Data availability
All information generated or examined in this study is included right here in the published article.
Abbreviations
MIC: Minimal inhibitory concentration
PD: Pharmacodynamic
PK: Pharmacokinetic
References
Jennings JD, Zielinski E, Tosti R, Ilyas AM. Septic arthritis of the wrist: Incidence, risk Factors, and predictors of infection. Orthopedics. 2017;40(3):e526–31. Google Scholar (http://scholar.google.com/scholarlookup?&title=Septic%20arthritis%20of%20the%20wrist%3A%20Incidence%2C%20risk%20Factors%2C%20and%20predictors%20of%20infection&journal=Orthopedics&volume=40&issue=3&pages=e526-31&publicationyear=2017&author=Jennings%2CJD&author=Zielinski%2CE&author=Tosti%2CR&author=Ilyas%2CAM)
Mercer HL, Rodriguez D, Rivas R, Rivenbark E, Mikola E, Mercer D. Management of the septic wrist: A systematic review of etiology and therapeutic strategies. Orthop Clin North Am. 2024;55(2):273–83. Google Scholar (http://scholar.google.com/scholarlookup?&title=Management%20of%20the%20septic%20wrist%3A%20A%20systematic%20review%20of%20etiology%20and%20therapeutic%20strategies&journal=Orthop%20Clin%20North%20Am&volume=55&issue=2&pages=273-83&publicationyear=2024&author=Mercer%2CHL&author=Rodriguez%2CD&author=Rivas%2CR&author=Rivenbark%2CE&author=Mikola%2CE&author=Mercer%2CD)
Société Française de Microbiologie. Gemella – Juin 2024 [Internet]. Paris: SFM. 2024 [cité 2025 avr 28]. Disponible sur: https://www.sfm-microbiologie.org/wp-content/uploads/2024/06/Gemellajuin2024.pdf
Domínguez-Gil M, Eiros JM, Klein C, Herrero J, Pastor L, Sarabia R. [Post-surgical meningitis by Gemella haemolysans]. Rev Esp Quimioter Publicacion Soc Esp Quimioter. 2018;31(1):60–2. Google Scholar (http://scholar.google.com/scholarlookup?&title=%5BPost-surgical%20meningitis%20by%20Gemella%20haemolysans%5D&journal=Rev%20Esp%20Quimioter%20Publicacion%20Soc%20Esp%20Quimioter&volume=31&issue=1&pages=60-2&publicationyear=2018&author=Dom%C3%ADnguez-Gil%2CM&author=Eiros%2CJM&author=Klein%2CC&author=Herrero%2CJ&author=Pastor%2CL&author=Sarabia%2CR)
Dini G, Verrotti A, Girella E, De Angelis F, Sardone M, Gorello P, et al. Infective endocarditis caused by Gemella haemolysans in a patient with bicuspid aortic valve: A case report. SAGE Open Med Case Rep. 2023;11:2050313X231211707. Google Scholar (http://scholar.google.com/scholarlookup?&title=Infective%20endocarditis%20caused%20by%20Gemella%20haemolysans%20in%20a%20patient%20with%20bicuspid%20aortic%20valve%3A%20A%20case%20report&journal=SAGE%20Open%20Med%20Case%20Rep&volume=11&publicationyear=2023&author=Dini%2CG&author=Verrotti%2CA&author=Girella%2CE&author=Angelis%2CF&author=Sardone%2CM&author=Gorello%2CP)
Patell K, Al Armashi AR, Somoza-Cano FJ, Ravakhah K, Han J. A rare case of Gemella haemolysans infection of knee arthroplasty. Cureus. 2021;13(8):e17073. Google Scholar (http://scholar.google.com/scholarlookup?&title=A%20rare%20case%20of%20Gemella%20haemolysans%20infection%20of%20knee%20arthroplasty&journal=Cureus&volume=13&issue=8&publicationyear=2021&author=Patell%2CK&author=Al%20Armashi%2CAR&author=Somoza-Cano%2CFJ&author=Ravakhah%2CK&author=Han%2CJ)
Rajagopal TS, Walia M, Wilson HA, Marshall RW, Andrade AJ, Iyer S. Gemella haemolysans spondylodiscitis: a report of two cases. J Bone Joint Surg Br. 2012;94(6):825–8. Google Scholar (http://scholar.google.com/scholarlookup?&title=Gemella%20haemolysans%20spondylodiscitis%3A%20a%20report%20of%20two%20cases&journal=J%20Bone%20Joint%20Surg%20Br&volume=94&issue=6&pages=825-8&publicationyear=2012&author=Rajagopal%2CTS&author=Walia%2CM&author=Wilson%2CHA&author=Marshall%2CRW&author=Andrade%2CAJ&author=Iyer%2CS)
Facklam R, Elliott JA. Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the Streptococci and enterococci. Clin Microbiol Rev. 1995;8(4):479–95. Google Scholar (http://scholar.google.com/scholarlookup?&title=Identification%2C%20classification%2C%20and%20clinical%20relevance%20of%20catalase-negative%2C%20gram-positive%20cocci%2C%20excluding%20the%20Streptococci%20and%20enterococci&journal=Clin%20Microbiol%20Rev&volume=8&issue=4&pages=479-95&publicationyear=1995&author=Facklam%2CR&author=Elliott%2CJA)
Salceanu SO, Levy S, Cunningham R, Frimpong-Ansah K. Severe Gemella haemolysans endophthalmitis following Ranibizumab intravitreal injection. Indian J Ophthalmol. 2017;65(11):1249–51. Google Scholar (http://scholar.google.com/scholarlookup?&title=Severe%20Gemella%20haemolysans%20endophthalmitis%20following%20Ranibizumab%20intravitreal%20injection&journal=Indian%20J%20Ophthalmol&volume=65&issue=11&pages=1249-51&publicationyear=2017&author=Salceanu%2CSO&author=Levy%2CS&author=Cunningham%2CR&author=Frimpong-Ansah%2CK)
Hadano Y, Kinugasa Y, Ohkusu K, Ishibashi K, Isoda M. Gemella haemolysans bacteremia in a patient with secondary peritonitis due to a duodenal ulcer perforation: A case report. IDCases. 2018;12:133–5. Google Scholar (http://scholar.google.com/scholarlookup?&title=Gemella%20haemolysans%20bacteremia%20in%20a%20patient%20with%20secondary%20peritonitis%20due%20to%20a%20duodenal%20ulcer%20perforation%3A%20A%20case%20report&journal=IDCases&volume=12&pages=133-5&publicationyear=2018&author=Hadano%2CY&author=Kinugasa%2CY&author=Ohkusu%2CK&author=Ishibashi%2CK&author=Isoda%2CM)
Fangous MS, Hémon F, Graf P, Samier-Guérin A, Alavi Z, Le Bars H, et al. Bone infections caused by Gemella haemolysans. Médecine Mal Infect. 2016;46(8):449–52. Google Scholar (http://scholar.google.com/scholarlookup?&title=Bone%20infections%20caused%20by%20Gemella%20haemolysans&journal=M%C3%A9decine%20Mal%20Infect&volume=46&issue=8&pages=449-52&publicationyear=2016&author=Fangous%2CMS&author=H%C3%A9mon%2CF&author=Graf%2CP&author=Samier-Gu%C3%A9rin%2CA&author=Alavi%2CZ&author=Bars%2CH)
Kassab NS, Alsammarraie N, Sarsam T, Al-Sammarraie M, Watt J. A rare case of gemella haemolysans endocarditis: a challenging diagnosis. Cureus. 2024 Jan.
Frésard A, Michel VP, Rueda X, Aubert G, Dorche G, Lucht F. Gemella haemolysans endocarditis. Clin Infect Dis Off Publ Infect Dis Soc Am. 1993;16(4):586–7. Google Scholar (http://scholar.google.com/scholarlookup?&title=Gemella%20haemolysans%20endocarditis&journal=Clin%20Infect%20Dis%20Off%20Publ%20Infect%20Dis%20Soc%20Am&volume=16&issue=4&pages=586-7&publicationyear=1993&author=Fr%C3%A9sard%2CA&author=Michel%2CVP&author=Rueda%2CX&author=Aubert%2CG&author=Dorche%2CG&author=Lucht%2CF)
Eslinger LJ, Ahmed T. Gemella haemolysans infective endocarditis in a patient with febrile neutropenia. Cureus. 2022 Apr.
Liu D, Bateman T, Carr E, Foster P. Endocarditis due to Gemella haemolysans in a newly diagnosed multiple myeloma patient. J Community Hosp Intern Med Perspect. 2016;6(4):32357. Google Scholar (http://scholar.google.com/scholarlookup?&title=Endocarditis%20due%20to%20Gemella%20haemolysans%20in%20a%20newly%20diagnosed%20multiple%20myeloma%20patient&journal=J%20Community%20Hosp%20Intern%20Med%20Perspect&volume=6&issue=4&publicationyear=2016&author=Liu%2CD&author=Bateman%2CT&author=Carr%2CE&author=Foster%2CP)
Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sörgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48(2):89–124. Google Scholar (http://scholar.google.com/scholarlookup?&title=Penetration%20of%20antibacterials%20into%20bone%3A%20pharmacokinetic%2C%20pharmacodynamic%20and%20bioanalytical%20considerations&journal=Clin%20Pharmacokinet&volume=48&issue=2&pages=89-124&publicationyear=2009&author=Landersdorfer%2CCB&author=Bulitta%2CJB&author=Kinzig%2CM&author=Holzgrabe%2CU&author=S%C3%B6rgel%2CF)
Furugaito M, Arai Y, Uzawa Y, Kamisako T, Ogura K, Okamoto S et al. Correction: furugaito antimicrobial susceptibility to 27 drugs and the molecular mechanisms of macrolide, tetracycline, and quinolone resistance in gemella sp. antibiotics. 2023, 12, 1538. Antibiot Basel Switz. 2024;13(6):515. Download references (https://citation-needed.springer.com/v2/references/10.1186/s12879-025-12160-2?format=refman&flavour=references)
Acknowledgements
Not applicable.
Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Department of Dermatology, Center Hospitalier Universitaire Amiens-Picardie, Amiens Cedex 1, 80045, France Camille Elbaz, P-A. Bruy & M. Doussiere
Department of Biology, Center Hospitalier Universitaire Amiens-Picardie, Amiens, France M. Choquet
Department of Infectiology, Center Hospitalier Universitaire Amiens-Picardie, Amiens, France J. P. Lanoix
Department of Rheumatology, Center Hospitalier Universitaire Amiens-Picardie, Amiens, France Y. Hamidou, P-A. Bruy, M. Doussiere & V. Goeb
Authors
- Camille Elbaz
- Y. Hamidou
- M. Choquet
- P-A. Bruy
- M. Doussiere
- J. P. Lanoix
- V. Goeb
Contributions
CE handled the clinical case and contributed to the literature review and manuscript drafting. MC assisted with the microbiological analysis and interpretation. YH oversaw clinical interpretation and manuscript revision. All authors reviewed and approved the final manuscript.
Corresponding author
Correspondence to Camille Elbaz.
Ethics declarations
Ethics approval and consent to participate
Not applicable. Ethical approval was not required for this case report, in accordance with local institutional policies.
Consent for publication
Written informed consent for publication of this case report and any accompanying data was obtained from the patient.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Reprints and permissions (https://s100.copyright.com/AppDispatchServlet?title=A%20case%20report%20of%20wrist%20arthritis%20caused%20by%20Gemella%20haemolysans&author=Camille%20Elbaz%20et%20al&contentID=10.1186%2Fs12879-025-12160-2©right=The%20Author%28s%29&publication=1471-2334&publicationDate=2025-11-22&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC-ND)
About this article
Cite this article
Elbaz, C., Hamidou, Y., Choquet, M. et al. A case report of wrist arthritis caused by Gemella haemolysans. BMC Infect Dis (2025). https://doi.org/10.1186/s12879-025-12160-2
Download citation (https://citation-needed.springer.com/v2/references/10.1186/s12879-025-12160-2?format=refman&flavour=citation)
*
Received: 31 August 2025
*
Accepted: 11 November 2025
*
Published: 22 November 2025
*
DOI: https://doi.org/10.1186/s12879-025-12160-2
Keywords
But here's where it gets controversial... What if the standard guidelines for antibiotic use aren't enough for these rare bugs? For beginners, septic arthritis simply means a joint infection that's often caused by bacteria, leading to pain, swelling, and sometimes fever. In this case, Gemella haemolysans—a usually harmless bacterium found in the mouth and gut—turned into a serious threat in a patient already fighting multiple health battles. The key twist? Amoxicillin, a common beta-lactam drug, didn't cut it alone, sparking debate on whether we should always jump to combo therapies for immunocompromised folks. And this is the part most people miss: without surgical intervention, how do we truly know if antibiotics alone suffice? It raises questions about tailoring treatments to the patient's overall health, not just the bug. Do you think current protocols need an overhaul for rarer infections like this? Or is combination therapy the default for at-risk groups? Share your thoughts in the comments—does this change how you view antibiotic resistance in complex cases?
